{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:12:30Z","timestamp":1778814750713,"version":"3.51.4"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Streptococcus pneumoniae continues to be an important bacterial pathogen associated with invasive (e.g. bacteraemia, meningitis) and non-invasive (e.g. community-acquired respiratory tract) infections worldwide. Surveillance studies conducted nationally and globally assist in determining trends over geographical areas and allow comparisons between countries.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To characterize invasive isolates of S. pneumoniae in terms of their serotype, antimicrobial resistance, genotype and virulence and to use the serotype data to determine the level of coverage by different generations of pneumococcal vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>SAVE (Streptococcus pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy in Canada) is an ongoing, annual, national collaborative study between the Canadian Antimicrobial Resistance Alliance (CARE) and the National Microbiology Laboratory, focused on characterizing invasive isolates of S. pneumoniae obtained across Canada. Clinical isolates from normally sterile sites were forwarded by participating hospital public health laboratories to the Public Health Agency of Canada\u2014National Microbiology Laboratory and CARE for centralized phenotypic and genotypic investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The four articles in this Supplement provide a comprehensive examination of the changing patterns of antimicrobial resistance and MDR, serotype distribution, genotypic relatedness and virulence of invasive S. pneumoniae obtained across Canada over a 10 year period (2011\u20132020).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The data highlight the evolution of S. pneumoniae under pressure by vaccination and antimicrobial usage, as well as vaccine coverage, allowing both clinicians and researchers nationally and globally to view the current status of invasive pneumococcal infections in Canada.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad064","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:31:30Z","timestamp":1683073890000},"page":"i2-i7","source":"Crossref","is-referenced-by-count":5,"title":["<i>\n                     <u>S<\/u>treptococcus pneumoniae<\/i> serotyping and antimicrobial susceptibility: <u>a<\/u>ssessment for <u>v<\/u>accine <u>e<\/u>fficacy in Canada after the introduction of PCV13"],"prefix":"10.1093","volume":"78","author":[{"given":"George G","family":"Zhanel","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745, Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Joseph P","family":"Lynch","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology Department of Medicine, David Geffen School of Medicine at UCLA , 10833 Le Conte Ave, Room 37-131 CHS, Los Angeles, CA 90095 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745, Bannatyne Avenue, Winnipeg, Manitoba R3E 0J9 , Canada"},{"name":"Clinical Microbiology, Shared Health , MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9 , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"2023050300310686800_dkad064-B1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2023050300310686800_dkad064-B2","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1093\/jac\/dkac255","article-title":"BSAC Vanguard series: tracking the global rise of antimicrobial resistance","volume":"77","author":"Murray","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0029-1202938","article-title":"Streptococcus pneumoniae: epidemiology risk factors and strategies for prevention","volume":"30","author":"Lynch","year":"2009","journal-title":"Sem Resp Crit Care Med"},{"key":"2023050300310686800_dkad064-B4","first-page":"217","article-title":"Streptococcus pneumoniae: antimicrobial resistance","volume":"16","author":"Lynch","year":"2010","journal-title":"Curr Opin Pulm Med"},{"issue":"Suppl 4","key":"2023050300310686800_dkad064-B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/dkz286","article-title":"Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007\u20132016","volume":"74","author":"Golden","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B6","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac043","article-title":"Community-acquired pneumonia in Canada during coronavirus disease 2019","volume":"9","author":"Mandell","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023050300310686800_dkad064-B7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/cid\/ciab645","article-title":"Dynamics of invasive pneumococcal disease in Israel in children and adults in the 13-valent pneumococcal conjugate vaccine (PCV13) era: a nationwide prospective surveillance","volume":"74","author":"Ben-Shimol","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023050300310686800_dkad064-B8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/cid\/ciab852","article-title":"Association of pneumococcal serotype with susceptibility to antimicrobial drugs: a systematic review and meta-analysis","volume":"75","author":"Andrejko","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023050300310686800_dkad064-B9","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01370-21","article-title":"Linear regression equations to predict \u03b2-lactam, macrolide, lincosamide and fluoroquinolone minimum inhibitory concentrations from molecular antimicrobial resistance determinants in Streptococcus pneumoniae","volume":"66","author":"Demczuk","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023050300310686800_dkad064-B10","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.vaccine.2022.02.081","article-title":"Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay","volume":"40","author":"LeBlanc","year":"2022","journal-title":"Vaccine"},{"key":"2023050300310686800_dkad064-B11","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1016\/j.vaccine.2021.08.061","article-title":"Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: focus on 22F and 33F from CANWARD 2007\u20132018","volume":"39","author":"Golden","year":"2021","journal-title":"Vaccine"},{"key":"2023050300310686800_dkad064-B12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jac\/dkac034","article-title":"PCV-15 and PPSV23 coverage of invasive and respiratory tract Streptococcus pneumoniae including MDR and XDR isolates: CANWARD 2007\u20132020","volume":"77","author":"Golden","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B13","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2021.115447","article-title":"Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011\u20132018","volume":"101","author":"Golden","year":"2021","journal-title":"Diag Microbiol Infect Dis"},{"key":"2023050300310686800_dkad064-B14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.tim.2022.06.001","article-title":"Factors affecting antimicrobial resistance in Streptococcus pneumoniae following vaccination introduction","volume":"30","author":"Watkins","year":"2022","journal-title":"Trends Microbiol"},{"key":"2023050300310686800_dkad064-B15","author":"National Advisory Committee on Immunization (NACI)","year":"2018"},{"key":"2023050300310686800_dkad064-B16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/21645515.2018.1532249","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults","volume":"15","author":"Stacey","year":"2019","journal-title":"Hum Vacc Immunother"},{"key":"2023050300310686800_dkad064-B17","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults 65 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine"},{"key":"2023050300310686800_dkad064-B18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023050300310686800_dkad064-B19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 7","key":"2023050300310686800_dkad064-B20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jac\/dky155","article-title":"Introduction to the SAVE study (2011\u201315): Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV-13","volume":"73","author":"Zhanel","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 7","key":"2023050300310686800_dkad064-B21","first-page":"5","article-title":"Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011\u20132015","volume":"73","author":"Karlowsky","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 7","key":"2023050300310686800_dkad064-B22","first-page":"12","article-title":"Analysis of multi-drug resistance (MDR) in the predominant invasive Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011\u20132015","volume":"73","author":"Adam","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 7","key":"2023050300310686800_dkad064-B23","first-page":"20","article-title":"Molecular characterization of Streptococcus pneumoniae isolates causing invasive infections in Canada: the SAVE study, 2011\u20132015","volume":"73","author":"Golden","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B24","doi-asserted-by":"crossref","first-page":"vii2","DOI":"10.1093\/jac\/dky155","article-title":"Introduction to the SAVE study (2011\u20132020): Streptococcus pneumoniae serotyping and antimicrobial susceptibility: assessment for vaccine efficacy in Canada after the introduction of PCV-13","volume":"73","author":"Zhanel","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B25","article-title":"Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011\u20132020","author":"Alford","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B26","article-title":"Analysis of multi-drug resistance in the predominant invasive Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011\u20132020","author":"Adam","year":"( )","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B27","article-title":"Genomic investigation of the most common Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011\u20132020","author":"Golden","year":"( )","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B28","article-title":"Comparison of PCV10, PCV13, PCV15, PCV-20 and PPSV23 vaccine coverage of Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011\u20132020","author":"Schellenberg","year":"( )","journal-title":"J Antimicrob Chemother"},{"key":"2023050300310686800_dkad064-B29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/cid\/ciab062","article-title":"Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a World Health Organization action framework","volume":"73","author":"Vekemans","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023050300310686800_dkad064-B30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","article-title":"The role of vaccines in combatting antimicrobial resistance","volume":"19","author":"Micoli","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"2023050300310686800_dkad064-B31","author":"Public Health Agency of Canada"},{"key":"2023050300310686800_dkad064-B32","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.613287","article-title":"Sugar-coated killer: serotype 3 pneumococcal disease","volume":"10","author":"Luck","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2023050300310686800_dkad064-B33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/vaccines8010132","article-title":"Development of next generation Streptococcus pneumoniae vaccines conferring broad protection","volume":"8","author":"Masomian","year":"2020","journal-title":"Vaccine"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/Supplement_1\/i2\/50168642\/dkad064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/Supplement_1\/i2\/50168642\/dkad064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:31:57Z","timestamp":1683073917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/Supplement_1\/i2\/7147763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":33,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2023,5,3]]},"published-print":{"date-parts":[[2023,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad064","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,22]]},"published":{"date-parts":[[2023,5,3]]}}}